跳至主要内容
临床试验/NCT02944097
NCT02944097已完成1 期

Study of the Oral Bioavailability of Trans-epsilon-viniferin and Trans-resveratrol From Native and Micellar Solubilized vineatrol30 Vine Extract

University of Hohenheim1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2015年3月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
12
试验地点
1
主要终点
Time to reach maximum plasma concentration (Tmax) of total trans-resveratrol [h]

研究概览

简要总结

To enhance the oral bioavailability of the antioxidants trans-resveratrol and trans-ε-viniferin from Vineatrol30 grapevine-shoot extract, the native powder was incorporated into micelles. A single dose, single blind, two arms crossover trial was conducted. Plasma and urine samples were collected at intervals up to 24 h after oral intake of native or micellar Vineatrol30 (500 mg), and resveratrol content was quantified and compared between formulations. Tolerability of the dose was also controlled by safety parameters in plasma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Healthy Volunteers with blood chemistry values within normal ranges
  • •Age: 18-35 years
  • •BMI: 19-25 kg/m2

排除标准

  • •Pregnancy or lactation
  • •Alcohol and/or drug abuse
  • •Use of dietary supplements or any medications, except contraceptives
  • •Any known malignant, metabolic and endocrine diseases
  • •Previous cardiac infarction
  • •Participation in a clinical trial within the past 6 weeks prior to recruitment
  • •Physical activity of more than 5 h/wk

研究组 & 干预措施

Vineatrol30 native powder

Experimental

500 mg Vineatrol30 containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin

干预措施: Vineatrol 30 native powder (Dietary Supplement)

Vineatrol30 micelles

Experimental

500 mg Vineatrol30 micelles containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin

干预措施: Vineatrol 30 micelles (Dietary Supplement)

结局指标

主要结局

Time to reach maximum plasma concentration (Tmax) of total trans-resveratrol [h]

时间窗: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose

Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase

Cumulative urinary excretion of total trans-epsilon-viniferin [nmol/g creatinine]

时间窗: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose

Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase

Mean maximum plasma concentration (Cmax) of total trans-epsilon-viniferin [nmol/L]

时间窗: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose

Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase

Time to reach maximum plasma concentration (Tmax) of total trans-epsilon-viniferin [h]

时间窗: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose

Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase

Cumulative urinary excretion of total trans-resveratrol [nmol/g creatinine]

时间窗: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose

Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase

Mean maximum plasma concentration (Cmax) of total trans-resveratrol [nmol/L]

时间窗: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose

Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase

Mean area under the curve (AUC) of plasma concentration vs. time of total trans-resveratrol [nmol/L*h]

时间窗: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose

Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase

Mean area under the curve (AUC) of plasma concentration vs. time of total trans-epsilon-viniferin [nmol/L*h]

时间窗: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose

Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase

次要结局

  • Serum triacylglycerols [mg/dL](0, 4, 24h post-dose)
  • Serum cystatin C [mg/mL](0, 4, 24h post-dose)
  • Serum aspartate transaminase activity [U/L](0, 4, 24h post-dose)
  • Serum gamma-glutamyl transferase activity [U/L](0, 4, 24h post-dose)
  • Serum alkaline phosphatase activity [U/L](0, 4, 24h post-dose)
  • LDL/HDL cholesterol ratio(0, 4, 24h post-dose)
  • Serum total cholesterol [mg/dL](0, 4, 24h post-dose)
  • Glomerular filtration rate [mL/min](0, 4, 24h post-dose)
  • Serum glucose [mg/dL](0, 24h post-dose)
  • Serum alanine transaminase activity [U/L](0, 4, 24h post-dose)
  • Serum creatinine [mg/dL](0, 4, 24h post-dose)
  • Serum bilirubin(0, 4, 24h post-dose)
  • Serum uric acid [mg/dL](0, 4, 24h post-dose)
  • Serum HDL cholesterol [mg/dL](0, 4, 24h post-dose)
  • Serum LDL cholesterol [mg/dL](0, 4, 24h post-dose)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验